Célpontalapú, szövettanitípus-agnosztikus daganatterápia és a tüdőrák

More than 6 million mutations of more than 600 cancer genes can occur in over 200 tumor types according to the COSMIC (Catalogue of Somatic Mutations in Cancer) data base. The theoretical combination of all „driver” alterations and tumor types adds up to an enormous number. There fore, there is a legitimate need to use the same targeted therapy in the presence of its target and mechanism of ac tion in multiple tumor types. The first tissue-agnostic drugs that are registered solely based on molecular biomarkers are the NTRK inhibitors (larotrectinib and entrectinib) and the PD-1 inhibitor pembrolizumab in microsatellite instable (MSI) and tumor mutation burden (TMB) high tumors. These targets are also present in lung cancer, and we have clinical proof of the activity of treatments. In addition, the molecular targets of many targeted therapies registered in other tu mor types occur in lung cancer for target-based tissue-ag nostic therapy planning in lung cancer. © PROFESSIONAL PUBLISHING HUNGARY.